SILK Silk Road Medical

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference

SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference.

Management is scheduled to present on Tuesday, May 14, 2024, at 3:40 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: .

About Silk Road Medical

Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit and connect on X, LinkedIn and Facebook.

Investor Contact:

Marissa Bych

Gilmartin Group



EN
23/04/2024

Underlying

SILKSilk Road Medical

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silk Road Medical

 PRESS RELEASE
Free
SILK Silk Road Medic...

Silk Road Medical Reports First Quarter 2024 Financial Results

Silk Road Medical Reports First Quarter 2024 Financial Results SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. “Our team delivered a strong start to 2024 as we deepened relationships with the physicians we serve and continued broadening our patient impact,” said Chas McKhann, CEO of Silk Road Medical. “In the first quarter, we made meaningful commercial progress while also taking steps ...

April 30, 2024 1 EN
 PRESS RELEASE
Free
SILK Silk Road Medic...

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Co...

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference. Management is scheduled to present on Tuesday, May 14, 2024, at 3:40 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: . About Silk Roa...

April 23, 2024 1 EN
 PRESS RELEASE
Free
SILK Silk Road Medic...

Silk Road Medical to Report First Quarter 2024 Financial Results on Ap...

Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024 SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Those interested in listening to the conference call should . Participants are encouraged to r...

April 9, 2024 1 EN
 PRESS RELEASE
Free
SILK Silk Road Medic...

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Tr...

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio. This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simpli...

April 2, 2024 1 EN
 PRESS RELEASE
Free
SILK Silk Road Medic...

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROU...

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System SUNNYVALE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States. This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anat...

March 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch